FDA approves Purdue Pharma’s Palladone
hydrochloride) capsules for the management of persistent moderate
to severe pain in patients requiring continuous opioid pain
relief for an extended period of time.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.
Haymarket Media Group launched an American version of the publisher's Campaign UK media brand this week.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.